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he transcription factor Krox-20 controls Schwann
cell myelination. Schwann cells in Krox-20 null mice
fail to myelinate, and unlike myelinating Schwann
cells, continue to proliferate and are susceptible to death.
We ﬁnd that enforced Krox-20 expression in Schwann cells
cell-autonomously inactivates the proliferative response of
Schwann cells to the major axonal mitogen 
 
 
 
–neuregulin-1
and the death response to TGF
 
 
 
 or serum deprivation. Even
in 3T3 ﬁbroblasts, Krox-20 not only blocks proliferation
and death but also activates the myelin genes periaxin and
T
 
protein zero, showing properties in common with master
regulatory genes in other cell types. Signiﬁcantly, a major
function of Krox-20 is to suppress the c-Jun NH
 
2
 
-terminal
protein kinase (JNK)–c-Jun pathway, activation of which is
required for both proliferation and death. Thus, Krox-20
can coordinately control suppression of mitogenic and
death responses. Krox-20 also up-regulates the scaffold
protein JNK-interacting protein 1 (JIP-1). We propose this as
a possible component of the mechanism by which Krox-20
regulates JNK activity during Schwann cell development.
 
Introduction
 
Myelination in rodent nerves starts around birth, when un-
identified axonal signals trigger a program of differentiation
in Schwann cells that results in the generation of the myelin
sheath, one of the most highly specialized cellular structures
in the body (Mirsky and Jessen, 1996, 2001; Zorick and
Lemke, 1996; Scherer and Arroyo, 2002). Here, we investigate
the molecular signaling underlying two key components of
 
the myelination program, namely cell cycle exit and appearance
of death resistance.
There is a strong temporal correlation between the onset
of myelination and the cessation of cell division, and analysis
with differentiation markers shows that although individual
cells still proliferate in the earliest stages of myelin differenti-
ation, they fall out of division before they start forming
myelin sheaths, as detected by elevation in expression of the
myelin protein Po (Friede and Samorajski, 1968; Brown and
Asbury, 1981; Stewart et al., 1993). Similarly, apoptotic
Schwann cell death declines in postnatal nerves as myelination
advances and apoptosis is largely restricted to nonmyelinating
cells (Grinspan et al., 1996; Syroid et al., 1996; Nakao et al.,
1997). In line with this, TGF
 
 
 
, a factor implicated as a death
signal in developing nerves, selectively induces apoptosis in
nonmyelinating cells, and spares cells expressing myelin
proteins (Parkinson et al., 2001).
Thus, Schwann cell myelination involves, first, escape
 
from the cell cycle and developmental death signaling,
followed by strong up-regulation of myelin proteins and
formation of compacted membrane wraps.
The transcription factor Krox-20 is essential for myelina-
tion. It is strongly up-regulated by axon associated signals
only in cells destined to myelinate and, in Krox-20 null
mice, although myelin differentiation starts (Parkinson et
al., 2003), myelin sheaths do not form and Schwann cells
continue to proliferate and remain susceptible to death
(Topilko et al., 1994; Zorick et al., 1999). In humans,
Krox-20 (Egr2) mutations are associated with Charcot-
Marie-Tooth, Dejerine-Sottas, and hereditary sensory and
motor neuropathies, underlining the pivotal role of this
protein in myelin formation (Wrabetz et al., 2001).
Here, we define the function of Krox-20 in Schwann cell
proliferation and death, and analyze the molecular signaling
that enables Krox-20 to control these events. We show that
expression of Krox-20 is sufficient to cell autonomously alter
the response of Schwann cells to the major axonal mitogen,
 
 
 
-neuregulin-1 (NRG-1), so that NRG-1 no longer stimu-
lates DNA synthesis. Similarly, Krox-20 inactivates TGF
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death signals and protects cells from death triggered by
growth factor deprivation. Notably, Krox-20 also blocks
proliferation and death in 3T3 fibroblasts, although these
cells are unrelated to Schwann cells. Moreover, in 3T3 fibro-
blast, Krox-20 triggers expression of the myelin genes peri-
axin and protein zero (P
 
0
 
), a function previously thought to
be a specific for Krox-20 in Schwann cells. We show a sig-
nificant relationship between Krox-20 signaling and the
c-Jun NH
 
2
 
-terminal kinase (JNK)–c-Jun pathway. We show
that this pathway is activated by both NRG-1 and TGF
 
 
 
 in
Schwann cells and that JNK/c-Jun activity is required for
proliferation and death. Importantly, Krox-20 suppresses
JNK/c-Jun signaling. This provides Krox-20 with a mecha-
nism for coordinated control of mitogenic and death sig-
naling in developing Schwann cells. Finally, we show
that Krox-20 regulates levels of JNK-interacting protein 1
(JIP-1), a scaffold protein that controls the activity of JNK-
mediated signaling (Davis, 2000). We propose this as a pos-
sible component of the mechanism by which Krox-20 regu-
lates the activity of JNK during Schwann cell development.
 
Results
 
Krox-20 blocks NRG-1–induced Schwann 
cell proliferation
 
In the absence of Krox-20, Schwann cells arrest at the earli-
est stage of myelin differentiation and remain proliferating
and death susceptible. To test whether expression of Krox-
20 alone is sufficient to remove cells from the cell cycle in
the face of NRG-1 stimulation, we infected Schwann cell
cultures with retroviral or adenoviral constructs expressing
full-length Krox-20 or the appropriate empty vector con-
trols. Krox-20 strongly reduced Schwann cell proliferation
in response to NRG-1 (Fig. 1, A and B) and caused a signif-
icant reduction in the induction of the early cell cycle
marker cyclin D1 after NRG-1 addition (Kim et al., 2001)
both by immunolabeling (P 
 
  
 
0.0001) and Western blot
(Fig. 1, C and D).
Krox-20–expressing cells also had elevated levels of the cell
cycle inhibitor p27 in immunolabeling experiments, an ob-
servation confirmed by two different p27 antibodies, and by
Western blotting (Fig. 1, E–I) in line with in vivo observa-
tions (Tikoo et al., 2000).
 
In the presence of Krox-20, Schwann cells are resistant 
to killing by TGF
 
 
 
 and growth factor deprivation
 
TGF
 
 
 
 acts as a death signal in immature Schwann cells
(Parkinson et al., 2001) and in mice without functional
TGF
 
 
 
 type II receptors, developmental Schwann cell death
Figure 1. Krox-20 inhibits DNA synthesis in Schwann cells. (A) The 
proliferation of Schwann cells, as measured by BrdU incorporation, 
in response to NRG-1 is inhibited by Krox-20. Schwann cells retro-
virally infected with empty vector (BP) or vector expressing Krox-20 
(K20) were treated with medium alone (Control) or with medium 
supplemented with 20 ng/ml NRG-1. The error bars represent 
one SD of the mean. (B) Inhibition of BrdU incorporation in cells 
expressing Krox-20. Cells infected with adenovirus coexpressing GFP 
and Krox-20 in control ( NRG-1) and 20 ng/ml NRG-1–treated cells. 
Note that GFP/Krox-20–positive cells are BrdU negative. Conversely, 
BrdU-positive cells are GFP negative (arrows). Bar, 20  m. (C and D) 
Krox-20 expression inhibits cyclin D1 induction in response to NRG-1. 
(C) The graph shows percentage of adenovirally infected GFP/cyclin 
D1–positive cells 6 h after addition of 20 ng/ml NRG-1 in GFP 
control (GFP) and GFP/Krox-20 (Krox-20)–expressing cells. The error 
bars represent one SD of the mean. (D) Western blot of cyclin D1 in 
GFP control (GFP) and GFP/Krox-20 (Krox-20) infected Schwann 
cells exposed to DM alone (Con) or DM containing 20 ng/ml NRG-1 
for 6 h. (E–I) Krox-20 expression increases levels of p27 protein in 
Schwann cells. (E–H) Immunolabeling of GFP (E and G) and GFP/
Krox-20 (F and H) infected Schwann cells with p27 antibody. Arrows 
indicate GFP/Krox-20 cells with elevated p27 protein. Bar, 20  m. 
(I) Western blot using p27 antibody of Schwann cells infected with 
either empty vector (BP) or Krox-20 (K20)–expressing retrovirus.
Figure 2. Krox-20 inhibits apoptosis of Schwann cells. (A and B) 
Krox-20 inhibits TGF -dependent apoptosis of Schwann cells. Sur-
vival assays for immunopanned Schwann cells infected with GFP or 
GFP/Krox-20 (Krox-20)–expressing adenovirus. Cells were treated 
for 24 h with TGF    TNF  (A) or TGF  alone (B) for 48 h and the 
number of surviving GFP-positive cells counted. (C) Krox-20 inhibits 
Schwann cell death after serum withdrawal. Survival assay of cells 
infected with GFP or GFP/Krox-20 (Krox-20)–expressing adenovirus. 
Surviving GFP-positive cells were counted 72 h after serum with-
drawal. The error bars represent one SD of the mean. 
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is strongly reduced (unpublished data). The escape from
death vulnerability and TGF
 
 
 
-induced apoptosis that ac-
companies myelin sheath formation does not take place in
Krox-20
 
 
 
/
 
 
 
 mice. To test whether presence of the Krox-20
protein is sufficient to induce death resistance and, in partic-
ular, to uncouple TGF
 
 
 
 stimulation from induction of
apoptosis, we performed survival assays on immunopanned
Schwann cells from newborn animals infected with Krox-
20/GFP adenovirus or GFP control virus. First, we found
that expression of Krox-20 strongly increased survival in re-
sponse to TGF
 
 
 
 plus TNF
 
 
 
 or TGF
 
 
 
 alone (P 
 
  
 
0.002
and P 
 
  
 
0.001, respectively; Fig. 2, A and B). Second, we
found that Krox-20–expressing cells survived 10% serum
withdrawal much better than control cells (Fig. 2 C; Cheng
et al., 2001). For both the TGF
 
 
 
 and serum withdrawal as-
says, Schwann cell death was confirmed to be apoptotic by
immunolabeling for the activated form of caspase-3 and
TUNEL analysis (Parkinson et al., 2001; unpublished data).
 
Krox-20 regulates proliferation, survival and myelin 
genes in 3T3 fibroblasts
 
Krox-20 expression induces myelin-differentiation genes in
Schwann cells (Nagarajan et al., 2001; Parkinson et al.,
2003). We show in a previous section (Krox-20 blocks NRG-
1–induced Schwann cell proliferation) that Krox-20 is also
sufficient to organize cell cycle withdrawal and confer death
resistance. This spectrum of activity has been associated with
master regulatory or selector genes. Because capacity to act in
a heterologous cell is a feature of some master regulators, we
tested whether Krox-20 could act in similar ways in cells not
related to Schwann cells, i.e., 3T3 fibroblasts.
We found that retrovirally sustained Krox-20 expression
blocked (P 
 
  
 
0.005) DNA synthesis of Swiss 3T3 cells in
response to PDGF-BB and prevented cyclin D1 induction
(Fig. 3, A and B). Krox-20 expression also suppressed the
proliferation of Swiss 3T3 and NIH 3T3 fibroblasts in do-
nor calf serum (unpublished data). Furthermore, Krox-20
inhibited apoptosis (P 
 
  
 
0.001) of NIH and Swiss 3T3 cells
after withdrawal of serum when measured by TUNEL anal-
Figure 3. Krox-20 regulates proliferation, survival and myelin 
gene expression in 3T3 fibroblasts. (A) Krox-20 expression inhibits 
PDGF-induced proliferation of Swiss 3T3 cells. Shown are the 
percentage of BrdU-positive cells in empty vector (BP) and Krox-20–
expressing (K20) cells in the absence (Control) and presence ( PDGF) 
of 5 ng/ml PDGF. The error bars represent one SD of the mean. (B) 
Krox-20 expression in Swiss 3T3 cells inhibits cyclin D1 induction 
in response to PDGF. Shown are control (BP) and Krox-20 (K20) 
infected cells, treated for 6 h with 5 ng/ml PDGF. The cells were 
double immunolabeled with Krox-20 (K20) and cyclin D1 (CycD1) 
antibodies, and counterstained with Hoechst dye (Ho). Bar, 20  m. 
(C) Krox-20 expression inhibits apoptosis of NIH 3T3 cells in serum-
free medium. The graph shows the percentage of TUNEL-positive 
cells in control (BP) and Krox-20 (K20)–expressing cells 48 h after 
serum withdrawal. The error bars represent one SD of the mean. 
(D–G) Krox-20 activates periaxin and P0 myelin protein expression 
in Swiss 3T3 cells. Swiss 3T3 cells were retrovirally infected with 
either empty vector (BP; D and F) or Krox-20 (K20; E and G), and 
immunolabeled with antibody against periaxin (Prx; D and E) or P0 
(F and G). Cells were counterstained with Hoechst dye (Ho) to reveal 
nuclei. Bar, 20  m. (H) Western blot of control (BP) or Krox-20 (K20) 
infected cells showing elevated periaxin and P0 protein levels.
Figure 4. Krox-20 does not inactivate NRG-1 or TGF  signaling. 
(A) Western blot analysis of control (GFP) and Krox-20 adenovirally 
infected Schwann cells, showing levels of ErbB2 and ErbB3 protein, 
together with activation (i.e., phosphorylation) of ERK1/2 and Akt in 
DM only and 10 min after addition of 20 ng/ml NRG-1. Shown also 
are the corresponding levels of periaxin in control cells and in cells 
expressing Krox-20. (B) NRG-1 receptor levels are not altered in 
Krox-20 /  nerves. Western blot of ErbB2 and ErbB3 in sciatic nerve 
from P10 wild-type ( / ), Krox-20 heterozygous ( / ) and Krox-20 
null ( / ) animals. (C–F) SMAD2 and SMAD4 proteins translocate 
normally to the nucleus in response to TGF  in Krox-20–expressing 
Schwann cells. Note intense nuclear labeling in cells infected with 
Krox-20–expressing adenovirus, treated for 1 h with 10 ng/ml TGF 1 
and immunolabeled with antibodies to either SMAD2 (C and D) or 
SMAD4 (E and F). Bar, 20  m. 
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ysis (Fig. 3 C; and not depicted). To our surprise, we found
that Krox-20 expression was also sufficient to up-regulate
the myelin genes periaxin and P
 
0
 
 in Swiss 3T3 cells. This in-
duction was unambiguous and seen both by immunohis-
tochemistry and Western blotting (Fig. 3, D–H).
These experiments show that Krox-20 can execute some
of its key Schwann cell functions in an unrelated cell. This,
together with the ability to induce a broad spectrum of dif-
ferentiation genes and withdraw cells from the cell cycle, is
reminiscent of master regulatory genes in other systems.
 
Krox-20 causes a selective modulation, rather than 
general inactivation of NRG-1 or TGF
 
 
 
 signaling in 
Schwann cells
 
The experiments in Figs. 1–3 provide a plausible explanation
for the increase in cell numbers, proliferation, and death in
Krox-20 mutants (Topilko et al., 1994; Zorick et al., 1999)
by showing that expression of Krox-20 is sufficient to alter
the response of Schwann cells to specific proliferation and
death factors present in peripheral nerves. We now set out to
examine the underlying molecular mechanisms.
 
We found that ErbB2 and ErbB3 NRG-1 receptor levels
were unchanged in cells infected with Krox-20/GFP adeno-
virus, and in nerves of Krox-20 null animals (Fig. 4, A and
B). Phosphorylation of the ERK1/2 MAPKs, both in un-
stimulated Schwann cells and in response to NRG-1, was
also unchanged by Krox-20 expression, at least in the condi-
tions used in our assay (Fig. 4 A). In addition, basal and
NRG-1–induced PI3-kinase activity, measured by phos-
phorylation of Akt, was not significantly affected by Krox-
20 expression (Fig. 4 A).
We also showed that two major members of the TGF
 
 
 
signaling pathway, SMAD2 and SMAD4, translocated nor-
mally to the nucleus in response to TGF
 
 
 
 in Krox-20–
expressing Schwann cells (Fig. 4, C–F; and not depicted).
In conclusion, the power of Krox-20 to inactivate mito-
genic and death signaling by NRG-1 and TGF
 
 
 
, respec-
tively, appears to be due to a selective modulation, rather
than general inactivation of the signaling pathways activated
by these factors. It is also noteworthy that, in Krox-20–
expressing cells, NRG-1 still activates two of the major kinases
involved in NRG-1–mediated proliferation, although the
Figure 5. Krox-20 inhibits the JNK–c-Jun 
pathway in vitro and in vivo. (A) Western 
blot (long exposure) showing suppression 
of phospho–c-Jun (P-cJun), c-Jun protein 
(cJun), and phospho-JNK1/2 (P-JNK1/2) 
in cells infected with Krox-20/GFP adeno-
virus for 48 h and maintained in DM 
alone. GFP indicates control cells infected 
with empty vector. (B–E) Krox-20 expres-
sion in Schwann cells inhibits NRG-1– 
(B and C) and TGF -dependent (D and E) 
activation of the JNK–c-Jun pathway. 
(B and D) Western blot of Schwann cells, 
20 h after adenoviral infection, treated 
with 20 ng/ml NRG-1 (B) or 10 ng/ml 
TGF  (D). Note inhibition of c-Jun phos-
phorylation by Krox-20 after growth factor 
addition compared with GFP control, 
whereas c-Jun protein levels are unaf-
fected. (C and E) Western of Schwann cells 
48 h after infection, treated with NRG-1 
(C) or TGF  (E). At this time point, both 
phospho–c-Jun and c-Jun proteins are 
suppressed by Krox-20 as compared with 
control cells. Either  -tubulin or GAPDH 
were used as loading controls. (F–M) 
c-Jun and Ser63 phospho–c-Jun immuno-
labeling of Schwann cells infected with 
either GFP (F, H, J, and L) or GFP/Krox-20 
(G, I, K, and M) and treated 48 h after 
infection with NRG-1 for 30 min. Both 
c-Jun and phospho–c-Jun levels are re-
duced in response to NRG-1 in Krox-20–
expressing cells compared with GFP 
control infected cells (arrows). (N and O) 
Teased preparation of sciatic nerve at E17, 
before myelination double labeled with 
c-Jun and Krox-20 antibodies. Hoechst 
nuclear dye (Ho) is used to visualize 
nuclei. Note that most/all nuclei contain 
c-Jun, whereas Krox-20 is not yet present. (P and Q) Teased preparation of sciatic nerve at P1 when many cells are myelinating. The nerves 
are double immunolabeled with Krox-20 (K20) and c-Jun (P) or phospho–c-Jun (PSer63c-Jun; Q) antibodies. Note that nuclei expressing Krox-20 
do not contain c-Jun or phospho–c-Jun. Bar, 20  m. 
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cells do not divide. The lack of mitogenic response must
therefore derive from interference with other intracellular
signaling molecules or pathways.
 
Krox-20 suppresses basal JNK/c-Jun activity, and inhibits 
NRG-1– and TGF
 
 
 
-stimulated JNK/c-Jun activation
 
The JNK–c-Jun pathway regulates proliferation and/or
death in several cell types (Leppa and Bohmann, 1999; Ham
et al., 2000), and in Schwann cells this pathway is required
for TGF
 
 
 
-induced apoptosis (Parkinson et al., 2001).
Therefore, we looked for a linkage between Krox-20 and
JNK/c-Jun signaling. First, we showed by double label im-
munohistochemistry that most/all Schwann cell nuclei ex-
pressed c-Jun and serine (Ser)63 phospho–c-Jun before my-
elination (E17), whereas neither antibody bound the Krox-
20–positive nuclei of early myelinating cells in neonatal
nerves, although they continued to label the nonmyelin cells
(Fig. 5, N–Q; and not depicted). This is consistent with the
absence of c-Jun in adult myelinating cells and the observed
fall in c-Jun levels during myelination in vivo and myelin in-
duction by cAMP elevation in vitro (Monuki et al., 1989;
De Felipe and Hunt, 1994; Stewart, 1995; Shy et al., 1996;
Awatramani et al., 2002).
Second, we found that expression of Krox-20 strikingly
suppressed basal JNK/c-Jun activity in cultured Schwann
cells, as judged by levels of phospho–c-Jun, c-Jun protein
and phospho-JNK1/2 (Fig. 5 A), and a reduction in the
number of c-Jun–positive nuclei in immunohistochemical
tests from 88.4
 
   
 
7% to 12.5
 
   
 
2% (P 
 
  
 
0.0001).
Third, in experiments involving short exposure to Krox-
20 (tests performed 20 h, rather than the usual 48 h, after
onset of adenoviral infection), we found that NRG-1– and
TGF
 
 
 
-stimulated phosphorylation of c-Jun was suppressed,
whereas levels of c-Jun protein still remained unchanged
(Fig. 5, B and D). At a later time point (48 h), both phos-
pho–c-Jun and c-Jun levels are reduced by Krox-20 (Fig. 5,
C and E). These findings were confirmed by immunolabel-
ing of cells expressing Krox-20 48 h after infection (Fig. 5,
F–M). These experiments show that Krox-20 expression
first blocks growth factor induced c-Jun phosphorylation,
whereas prolonged Krox-20 expression also reduces c-Jun
protein levels in Schwann cells.
Together, these experiments indicate that the JNK–c-Jun
pathway is inactivated in individual cells as they start myelin-
ation and that this takes place as a consequence of Krox-20
activation. We now asked whether this JNK/c-Jun inactiva-
tion was, in turn, sufficient to explain the effects of Krox-20
on NRG-1–driven proliferation and TGF
 
 
 
-induced death.
 
Down-regulation of the JNK–c-Jun pathway is sufficient 
to uncouple NRG-1 receptor activation from mitogenesis
 
To test whether NRG-1 stimulation of Schwann cell prolif-
eration depended on the JNK–c-Jun pathway, we blocked
JNK activity in cultured Schwann cells using two methods.
First, we used SP600125, a selective inhibitor of JNK1 and
JNK2 (Bennett et al., 2001). Having confirmed that 30 
 
 
 
M
SP600125 completely prevented JNK1/2 and c-Jun phos-
phorylation even in the presence of 20 ng/ml NRG-1 (Fig. 6
A), we found that SP600125 blocked Schwann cell DNA
synthesis in response to 20 ng/ml NRG-1 in a dose-depen-
dent manner (Fig. 6 B). Second, we performed experiments
expressing the JNK binding domain (JBD) of the JNK bind-
ing protein JIP-1, which specifically inhibits JNK activity
and c-Jun phosphorylation (Harding et al., 2001). In confir-
mation of this, JBD expression blocked c-Jun phosphoryla-
tion, but not ERK1/2 activation, in response to NRG-1
(Fig. 6 C). We found that JBD expression significantly (P 
 
 
 
0.001) inhibited 20 ng/ml NRG-1–stimulated BrdU incor-
poration (Fig. 6 D). Furthermore, JBD expression inhibited
Schwann cell death in response to TGF
 
 
 
 or serum with-
drawal (unpublished data).
Although Krox-20 is likely to have numerous effects on
intracellular signaling in Schwann cells, these observations
argue that the Krox-20–mediated inactivation of the JNK–
c-Jun pathway is sufficient to cause the proliferation arrest
seen in Krox-20–positive Schwann cells.
 
Death prevention by Krox-20 depends on 
Krox-20–mediated inactivation of JNK
 
Killing of Schwann cells by TGF
 
 
 
 depends on the activation
of the JNK–c-Jun pathway (Parkinson et al., 2001), an event
that is inhibited by Krox-20 (Fig. 5). This provides a plausi-
ble explanation for the protective effects of Krox-20 against
TGF
 
 
 
-induced cell death. It also predicts that enforced acti-
vation of this pathway in Krox-20–expressing cells should
restore their vulnerability to cell death. To reactivate the
JNK pathway in Krox-20–expressing cells, we used activated
forms of either MEKK1 (Olson et al., 1995; Whitfield et al.,
Figure 6. Inhibition of the JNK pathway inhibits NRG-1–dependent 
proliferation of Schwann cells. (A) Western blot showing inhibition 
of NRG-1–induced JNK and c-Jun phosphorylation by 30  M 
SP600125 (SP6). (B) Percentage of BrdU-positive Schwann cells in 
DM only (Cont.) and in medium containing 20 ng/ml NRG-1 in the 
absence or presence of increasing concentrations of the JNK inhibitor 
SP600125 as indicated. The error bars represent one SD of the mean. 
(C) Expression of the JBD of JIP-1 inhibits NRG-1–induced c-Jun 
phosphorylation, but not ERK1/2 activation. (D) Percentage of 
BrdU-positive Schwann cells infected with control virus expressing 
GFP only (GFP) or JBD-expressing adenovirus in the absence (Cont.) 
or presence of 20 ng/ml NRG-1. The error bars represent one SD of 
the mean. 
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2001) or MKK7 (MKK7D; Wang et al., 1998) kinases.
Cultured Schwann cells were coinfected with the Krox-20/
GFP and either myc-tagged MEKK1- or MKK7D-express-
ing adenoviruses. Immunolabeling of infected cells showed
that 
 
 
 
90% of GFP-positive (Krox-20–expressing) Schwann
cells also expressed MEKK1 (unpublished data). In these
double infected cells, MEKK1 and MKK7D reversed the
Krox-20–mediated inhibition of c-Jun phosphorylation both
by Western blot and immunolabeling (Fig. 7 A; and not
depicted). To test the effects of MEKK1 or MKK7D on cell
death in Krox-20 cells, double infected Krox-20/MEKK1
or Krox-20/MKK7D cells were subjected to the serum with-
drawal test (Fig. 2). This showed that most of the cells
expressing Krox-20 and a control LacZ adenovirus were
protected from death as expected. In contrast, the cells ex-
pressing Krox-20/MEKK1 or Krox-20/MKK7D died as ex-
pected for uninfected native cells (Fig. 7 B).
Thus, reactivation of the JNK–c-Jun pathway in cells ex-
pressing Krox-20 overrides the protective effect of Krox-20.
This strengthens our conclusion that the death protection by
Krox-20 that we have described in Fig. 2 can be attributed
to Krox-20–mediated inactivation of JNK.
 
JIP-1, a potential suppressor of JNK activity, 
is up-regulated by Krox-20
 
There is evidence that up-regulation of the JNK scaffolding
protein JIP-1 (IB1) may in some circumstances inactivate
JNK signaling (Bonny et al., 2000; Tawadros et al., 2002).
A number of observations were consistent with the idea that
JIP-1 is involved in mediating the inhibitory effect of Krox-
20 on JNK. First, expression of Krox-20 strongly increased
JIP-1 protein levels in Schwann cells in vitro, and we also
observed a higher migrating band, which may represent a
phosphorylated form of the JIP-1 protein (Fig. 8 A; Meyer
et al., 1999). Second, in Krox-20 null mice the levels of
JIP-1 protein were substantially reduced, whereas c-Jun levels
were elevated (Fig. 8 B). Third, JIP-1 and Krox-20 mRNAs
were up-regulated with a similar time course during nerve
development, and the JIP-1 mRNA and protein that local-
ized to paranodal regions decreased after nerve cut (Fig. 8,
C, F, and G; and not depicted; Nagarajan et al., 2002). A
Figure 7. Expression of MEKK1 or MKK7D and the resulting acti-
vation of c-Jun phosphorylation restores vulnerability to death in 
cells expressing Krox-20. (A) Western blot showing induction of 
c-Jun phosphorylation in Schwann cells coexpressing Krox-20 and 
either MEKK1 (K20/MEKK1) or MKK7D (K20/MKK7D) as compared 
with control (K20/LacZ) cells. (B) Serum withdrawal survival assay 
of Krox-20/LacZ, Krox-20/MEKK1 or Krox-20/MKK7D–expressing 
Schwann cells. The death protection offered by Krox-20 alone 
(Fig. 2 C) is not seen in Krox-20/MEKK1 or Krox-20/MKK7D–
expressing cells. The error bars represent one SD of the mean.
Figure 8. Regulation of JIP-1 during sciatic development. 
(A) Western blot of GFP and Krox-20/GFP (K20) adenovi-
rally infected Schwann cells showing increased levels of 
JIP-1 in Krox-20–expressing cells. (B) JIP-1 protein levels 
are reduced, and c-Jun levels increased, in sciatic nerve 
from P9 and P12 Krox-20 null animals ( / ) compared 
with wild type ( / ). (C) Semi-quantitative PCR analysis of JIP-1 mRNA expression in sciatic nerve during development from embryonic day 
14 (E14) to P12 and at P12, 5 d after nerve cut (P12/CUT). (D) Expression of JIP-1 inhibits c-Jun phosphorylation in Schwann cells. Shown are 
the percentage of Ser63 phospho–c-Jun–positive cells for cells cotransfected with either GFP-expressing plasmid, for identification of transfected 
cells, plus empty vector (GFP/EV) or GFP plus JIP-1 (GFP/JIP-1)–expressing plasmids. The error bars represent one SD of the mean. (E) Western 
blot showing that, unlike Krox-20, JIP-1 expression does not reduce c-Jun protein levels in Schwann cells. (F and G) Immunolabeling of P12 
sciatic nerve showing phase (F) and JIP-1 immunofluorescence (G). Arrows indicate localization of JIP-1 in the paranodal loops of myelinating 
Schwann cells. 
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comparable profile of JIP-1 mRNA expression was found
using Affymetrix gene arrays (unpublished data). Lastly, ex-
pression of JIP-1 selectively reduced (P 
 
  
 
0.0001) the per-
centage of Ser63 phosphorylated c-Jun–positive Schwann
cells maintained under basal conditions in vitro, whereas
leaving c-Jun protein levels unchanged (Fig. 8, D and E).
Together, these experiments suggest that JIP-1 may act as a
link in the chain that leads from Krox-20 to inhibition of
JNK and reduced phospho–c-Jun.
 
Discussion
 
Krox-20 controls the outcome of NRG-1 and TGF  
signaling in Schwann cells
The first report on Krox-20 inactivation in Schwann cells
showed that Krox-20 nerves contained an increased num-
ber of Schwann cells (Topilko et al., 1994). Further work
revealed that the rates of DNA synthesis and apoptosis
were increased in these nerves, and that levels of the tran-
scription factor Oct-6 (SCIP) remained high, although
they fall in normal nerves (Zorick et al., 1999). It was plau-
sibly suggested that the ongoing Oct-6 expression might be
responsible for the high proliferation rate, and that the in-
creased death could be a downstream consequence of this,
because a larger Schwann cell population would result in
increased competition for limited amounts of axon-associ-
ated survival signals (Zorick et al., 1999). In the first part
of this paper, we provide an alternative explanation for the
changes in proliferation and death seen in Krox-20 / 
nerves. We show that Krox-20 cell autonomously alters the
response of Schwann cells to NRG-1, the major axonal mi-
togen in neonatal nerves, so that NRG-1 no longer stimu-
lates DNA synthesis. Krox-20 is activated as cells start to
myelinate and this is correlated with cessation of prolifera-
tion. We suggest that this is due to the ability of Krox-20
to signal cell cycle exit, even in the presence of mitogens.
In Krox-20 /  nerves, this mechanism is compromised,
resulting in ongoing proliferative response to mitogens
such as NRG-1.
The increased apoptosis in nerves of Krox-20 mutants can
also be related to cell-autonomous effects of Krox-20, be-
cause we find that Krox-20 expression provides cells with
strong protection against apoptotic death. This effect is
broad based, in the sense that Krox-20 expression protects
Schwann cells from TGF  killing and safeguards both
Schwann cells and 3T3 fibroblasts from death by growth
factor deprivation. Therefore, it is likely that the death resis-
tance that cells acquire as they start to myelinate (Grinspan
et al., 1996; Parkinson et al., 2001) is due to the presence of
Krox-20 in these cells. We suggest that in Krox-20 / 
nerves, Schwann cells are bereft of this protection and conse-
quently die in large numbers (Zorick et al., 1999).
As to the alternative possibility that increased death in
nerves of P12 Krox-20 mutants is due to enhanced compe-
tition for axonal survival signals, this is now less attractive,
because it is realized that postnatal Schwann cells support
their own survival by autocrine signaling, and that death of
these cells is not increased even when axons are cut (Grin-
span et al., 1996; Cheng et al., 1998; Dowsing et al., 1999;
Meier et al., 1999).
Krox-20 shares similarities with master regulatory genes
Unexpectedly, constitutive expression of Krox-20 caused the
myelin proteins periaxin and P0 to be expressed in 3T3 fi-
broblasts, cells that do not normally express these proteins,
and are unrelated to Schwann cells. Periaxin and P0 show ex-
tremely restricted distribution in vivo, being largely confined
to myelinating Schwann cells in the adult peripheral nervous
system (Scherer et al., 1995; Lee et al., 1997).
We also observed that Krox-20 induces growth arrest and a
decrease in cyclin D1 levels not only in Schwann cells but
also in fibroblastic Swiss 3T3 cells treated with PDGF, a clas-
sical mitogen for these cells (Withers et al., 1995). This agrees
with previous data showing c-Jun transactivates the cyclin D1
promoter (Sabbah et al., 1999; Wisdom et al., 1999). Fur-
thermore, Krox-20 protects 3T3 cells, like Schwann cells,
from death induced by growth factor deprivation.
The present experiments and previous work (Nagarajan et
al., 2001; Parkinson et al., 2003) show that Krox-20 activates
a large range of myelin differentiation genes and proteins, or-
ganizes cell cycle exit and protects from death. It can also exe-
cute some of its key actions in a heterologous cell. Therefore,
Krox-20 acts in many ways in a manner expected of a master
regulator for myelin Schwann cells, and has several of the
properties of master regulatory genes such as MyoD, the neu-
ral basic helix-loop-helix genes, or PPAR  (Davis et al.,
1987; Tontonoz et al., 1994; Lee et al., 1995; Lo et al., 1998;
Zorick et al., 1999; Sabourin and Rudnicki, 2000).
Krox-20 suppresses the JNK–c-Jun pathway
We find that constitutive expression of Krox-20 in cultured
Schwann cells results in down-regulation of the JNK–c-Jun
pathway under basal conditions, and suppression of JNK/
c-Jun activation by NRG-1 and TGF . This inhibitory in-
teraction between Krox-20 and c-Jun is likely to reflect the
action of Krox-20 in vivo. The principal evidence is the ex-
cellent negative correlation we see between expression of Krox-
20 on the one hand and c-Jun and phosphorylated c-Jun on
the other in the nuclei of individual Schwann cells in neona-
tal nerves. Earlier work also supports this conclusion. Adult
myelinating cells express Krox-20 but not c-Jun, although it
is detectable in nonmyelinating cells (Shy et al., 1996). After
nerve transection, c-Jun levels rise as Schwann cells dediffer-
entiate and Krox-20 levels fall, whereas during regeneration
c-Jun falls and Krox-20 expression increases as cells establish
new myelin sheaths (De Felipe and Hunt, 1994; Stewart,
1995; Shy et al., 1996; Topilko and Meijer, 2001).
Suppression of the JNK–c-Jun pathway reduces 
proliferation and death in Schwann cells
We find that inhibition of JNK in two unrelated ways, i.e.,
by the small molecular blocker SP600125 or by the JBD of
JIP-1, uncouples NRG-1 stimulation from DNA synthesis.
The JNK–c-Jun pathway has not previously been implicated
in Schwann cell proliferation. The expression pattern of
c-Jun is, however, consistent with such a role. c-Jun is high
in embryonic nerves before myelination when proliferation
is ongoing, low in mature nerves where proliferation is ab-
sent and high in transected nerves (previous paragraph). Al-
though our experiments indicate that JNK/c-Jun activity is
necessary for Schwann cell proliferation, at least in response392 The Journal of Cell Biology | Volume 164, Number 3, 2004
to NRG-1, it is not sufficient. We see this in Schwann cells
maintained in medium without mitogens in vitro and in the
distal stump of nerves several weeks after transection. In
both cases, proliferation is low or absent but c-Jun expres-
sion is relatively high.
The observation that the JNK–c-Jun pathway is required
for NRG-1–driven Schwann cell proliferation indicates that
the antiproliferative effect of Krox-20 can be attributed to
the ability of this transcription factor to inactivate this path-
way, as evidenced by down-regulation of c-Jun protein,
phosphorylated c-Jun, and phosphorylated JNK. Although
the data indicate that suppression of the JNK–c-Jun path-
way is sufficient to account for the effects of Krox-20 on
proliferation, it is possible that Krox-20 has additional ac-
tions in Schwann cells that also contribute to cell cycle exit.
This is suggested by the Krox-20–mediated induction of the
cell cycle inhibitor p27.
We have shown previously that TGF -induced death in-
volves phosphorylation of c-Jun, that an active form of c-Jun
kills Schwann cells and that a dominant negative form of
c-Jun inhibits TGF -induced death (Parkinson et al., 2001).
Therefore, as in some other cell types (Kyriakis and Avruch,
2001; Shaulian and Karin, 2002), the JNK–c-Jun pathway
is a component of at least two signaling cascades in Schwann
cells, those that promote death and those that promote pro-
liferation. This dual function allows Krox-20 to suppress
both cell division and death through a single action, namely
inactivation of the JNK–c-Jun pathway.
Regulation of JIP-1 by Krox-20 during Schwann 
cell development
JNK signaling is regulated by the balance between upstream
activating kinases such as MKK4/7 and protein phospha-
tases, which act to turn off JNK activity (Camps et al., 2000;
Weston and Davis, 2002). Another layer of JNK regulation
has been revealed with the identification of JIP-1, which acts
as a scaffold protein and binds the mixed lineage kinase
MLK3, the MAPK MKK7, and JNK1/2 (Dickens et al.,
1997; Whitmarsh et al., 1998).
JIP-1 potentiates the activation of JNK by MKK7. How-
ever, JIP-1 can also inhibit JNK–c-Jun interactions (Dickens
et al., 1997), which would lead to reduced c-Jun phosphory-
lation, and there are a number of reports that increased levels
of JIP-1 suppress JNK signaling (Dickens et al., 1997;
Bonny et al., 2000; Tawadros et al., 2002).
Our finding that JIP-1 is present and developmentally
regulated in peripheral nerve and a target of Krox-20 is of
great interest, because this may be part of the mechanism by
which Krox-20 suppresses JNK/c-Jun activation. Notably,
neither expression of the JBD region or full-length JIP-1,
both of which reduce c-Jun phosphorylation, affected c-Jun
protein levels in Schwann cells. The mechanism by which
Krox-20 suppresses c-Jun protein therefore remains to be
discovered. The localization of JIP-1 in the paranodal region
of the myelinating Schwann cells is also of interest. JIP-1
binds the RhoA exchange factor, RhoGEF190 (Meyer et al.,
1999), and a similar localization was observed for RhoA in
Schwann cells (Scherer and Gutmann, 1996), raising the
possibility that JIP-1 may function in regulation of Rho ac-
tivity in Schwann cells.
Materials and methods
Materials
Antibody to BrdU and FuGene6 transfection reagent were purchased from
Roche Diagnostics Ltd. Antibody against c-Jun and SMAD2 were pur-
chased from BD Biosciences. Antibodies against ERK1/2, phosphorylated
JNK1/2 (Thr183/Tyr185), JNK1/2, and Ser473 phospho-Akt were pur-
chased from Cell Signaling Technology (New England Biolabs, Inc.). Anti-
bodies against phosphorylated ERK1/2 and the FLAG tag were purchased
from Sigma-Aldrich. mAb against cyclin D1, SMAD4, and pAbs against
ErbB2, ErbB3, and p27 were purchased from Santa Cruz Biotechnology,
Inc. mAb against JIP-1 and JIP-1b expression construct were gifts from A.
Whitmarsh (University of Manchester, Manchester, UK; Yasuda et al.,
1999). Adenoviral constructs expressing EGFP and EGFP/Krox-20 were a
gift from J. Milbrandt (Washington School of Medicine, St. Louis, MO; Na-
garajan et al., 2001). Adenovirus expressing  -galactosidase and activated
MEKK1, and antibody against the Ser63 phosphorylated form of c-Jun were
gifts from J. Ham (University College London; Lallemand et al., 1998;
Whitfield et al., 2001). Adenovirus expressing the FLAG-tagged JBD of JIP-1
(Harding et al., 2001) was a gift from J. Uney (University of Bristol, Bristol,
UK); adenovirus expressing active MKK7 (MKK7D) was a gift from Y.
Wang (University of California Los Angeles, CA; Wang et al., 1998); and
adenovirus expressing JIP-1 was a gift from J.-A. Haefliger (University Hos-
pital, Lausanne, Switzerland; Tawadros et al., 2002). Recombinant TGF 1
and heregulin  1 (referred to as NRG-1) were purchased from R&D Sys-
tems. Krox-20 null mice were a gift from P. Charnay (Ecole Normale Su-
perieure, Paris, France). Sources of other reagents have been detailed else-
where (Morgan et al., 1991, 1994; Archelos et al., 1993; Gillespie et al.,
1994; Jessen et al., 1994; Dong et al., 1995; Stewart, 1995; Meier et al.,
1999; Parkinson et al., 2001, 2003).
Cell culture
Schwann cells were prepared from the sciatic nerve and brachial plexus
from newborn or 3-d-old rats (Brockes et al., 1979; Morgan et al., 1991).
Schwann cells for TGF -induced apoptosis studies were prepared by im-
munopanning and used directly (Dong et al., 1999). Schwann cells were
cultured unless otherwise stated in serum-free supplemented medium (Jes-
sen et al., 1994) containing 10
 6 M insulin, referred to as defined medium
(DM). For adenoviral infection experiments, serum-purified Schwann cells
were plated at a density of 5,000 cells in a 15- l drop on poly-D-lysine/
laminin–coated coverslips. For preparation of adenovirally infected cells
for Western blot, serum-purified, or immunopanned Schwann cells were
infected as described previously (Parkinson et al., 2001). For retroviral in-
fection of Schwann cells, cells were cultured in DME supplemented with
3% FCS/2  M forskolin/20 ng/ml NRG-1, and infected using retroviral su-
pernatant from GP E packaging cells as described previously (Parkinson
et al., 2001, 2003). NIH 3T3 and Swiss 3T3 fibroblasts were cultured in
DME/10% donor calf serum for infection using retroviral supernatants.
Transient transfections and Krox-20 genotyping were prepared as de-
scribed previously (Schneider-Maunoury et al., 1993; Parkinson et al.,
2001, 2003).
Cell survival assays
Schwann cells were infected with GFP control, Krox-20/GFP, or JBD-
expressing adenovirus. 24 h later, cells were changed into DM. 6 h later,
time 0 controls were fixed, whereas remaining cells were changed into
DM or medium containing a combination of 20 ng/ml TGF 1 plus 40 ng/
ml TNF  or 20 ng/ml TGF 1 alone in DM. The relationship between cell
survival and death in this assay has been extensively characterized and is
reciprocal and cell survival was assessed as described previously (Meier et
al., 1999; Parkinson et al., 2001). For 24-h survival assays with TGF 1
plus TNF , percentage of survival is shown relative to time 0 controls. For
TGF 1 assays, percentage of survival is relative to 48 h untreated controls.
For survival assays after serum withdrawal, Schwann cells were adenovi-
rally infected in DME containing 10% FCS. 24 h after infection, time 0
controls were fixed, whereas remaining cells were changed into DME
alone; cells were fixed after 72 h. Results shown are pooled from three in-
dependent experiments. TUNEL analysis and immunolabeling for acti-
vated caspase-3 were performed as described previously (Gavrieli et al.,
1992; Parkinson et al., 2001).
Immunocytochemistry
Immunolabeling with BrdU, P0, and JIP-1 antibodies was performed as de-
scribed previously (Morgan et al., 1991; Stewart et al., 1993; Willoughby
et al., 2003). For all other antibodies, cells were fixed in 4% PFA in PBS,
pH 7.5, for 10 min. For immunolabeling with Ser63 phospho-Jun antibod-Krox-20 regulates JNK/c-Jun in Schwann cells | Parkinson et al. 393
ies, cells were permeabilized in 0.5% Triton X-100/PBS for 5 min followed
by a block of 50% goat serum/1% BSA/PBS for 30 min; the antibody was
diluted in 1% BSA and left overnight at 4 C. For other antibodies, after fix-
ing cells were permeabilized and blocked in antibody diluting solution
(PBS containing 10% calf serum, 0.1 M lysine, 0.2% sodium azide) supple-
mented with 0.2% Triton X-100 for 30 min. Primary and secondary anti-
bodies were diluted and applied in antibody diluting solution, with the
secondary antibody conjugated to either FITC or Cy3. Coverslips were
mounted in Citifluor (Citifluor Ltd.), and examined at RT with a fluores-
cence microscope (model Eclipse E800; Nikon). Images were captured at
40  magnification, using a digital camera (model DXM1200; Nikon), and
ACT-1 acquisition software (Nikon). Pictures were digitalized using UMAX
PowerLookIII scanner and figures were prepared using Adobe Photoshop
version 5.0.
Western blot analysis
40  g of protein extracts were electrophoresed on 10% SDS-polyacryl-
amide gels, transferred onto nitrocellulose membranes (Hybond ECL; Am-
ersham Biosciences), blocked with 5% fat-free milk in TBS/0.1% Tween
20, and incubated with primary antibodies in this block solution. Mem-
branes were washed in TBS/Tween 20 and secondary antibody added in
this solution. Specific protein complexes were revealed using ECL Plus
chemiluminescent reagent (Amersham Biosciences).
PCR
For PCR analysis, RNA was isolated from sciatic nerves of rats at E14, E18,
P7, P12, and P12 cut at P7, using TRIzol reagent (Invitrogen) according to
the manufacturer’s instructions. First strand cDNA was synthesized from
total RNA using oligo dT primers (Promega) and Avian Myeloblastosis Vi-
rus reverse transcriptase (Promega). Oligonucleotide primers (Invitrogen)
were used to amplify sequences containing the JIP-1 (5 -CGACTGTCTGT-
CATCCCCAG-3  and 5 -CATAGACAGTGGCAGAGTCG-3 ) and GAPDH
(5 -ACCACAGTCCATGCCATCAC-3  and 5 -TCCACCACCCTGTTGCT-
GTA-3 ). The PCR amplification program consisted of denaturation at 95 C
for 30 s, annealing at 55 C for 1 min, and extension at 72 C for 1 min for
35 cycles.
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